阻断CD40/CD40L 相互作用延长移植物抗宿主病小鼠存活时间

中国临床药理学与治疗学 ›› 2003, Vol. 8 ›› Issue (1): 6-10.

阻断CD40/CD40L 相互作用延长移植物抗宿主病小鼠存活时间

刘荷中, 毛宁, 侯春梅, 李秀森, 沈倍奋, 唐佩弦

军事医学科学院基础医学研究所, 北京 100850

收稿日期:2002-10-11 修回日期:2002-10-28 发布日期:2020-11-25
通讯作者: 唐佩弦, 男, 博士生导师, 研究员, 主要从事细胞生物学、实验血液学和干细胞生物学等方面的研究。Tel:010-66930551 E-mail:pxtang@a-1.net.cn
作者简介:刘荷中, 男, 博士, 助理研究员, 主要从事细胞生物学、免疫学和病毒学等方面的研究, 现正致力于丙型肝炎病毒体外感染模型的研究。Tel:010-66932308 E-mail:andi1971@sina.com

Blockade of CD40/CD40L interactions prolongs the survival time of mice with graft-versus-host disease

LIU He-Zhong, MAO Ning, HOU Chun-Mei, LI Xiu-Sen, TANG Pei-Xian, SHEN Bei-Fen

Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing 100850

Received:2002-10-11 Revised:2002-10-28 Published:2020-11-25

摘要/Abstract

摘要： 目的: 克隆表达人CD40-Ig 融合蛋白, 并在小鼠移植物抗宿主病(GVHD) 模型中研究利用其阻断CD40 CD40L 相互作用的保护性效果。方法: 利用RT-PCR 技术自人Daudi 细胞系中克隆CD40 基因胞外区, 并插入含有人IgG1 Fc 段基因的pIG1 载体中,构建携带CD40-Fc 融合基因的瞬时表达载体转染COS-7 细胞, 间接夹心ELISA 法检测CD40-Ig 融合蛋白的表达。再将CD4-Fc 融合基因连接入pcDNA3.1的相应位点构建稳定表达载体转染CHO 细胞, 筛选分泌CD40-Ig 融合蛋白的阳性重组CHO 细胞并进行无血清大规模培养, 收获培养上清利用Protein A 亲和层析法纯化融合蛋白。SDS-PAGE、Western blot 和配基结合实验鉴定CD40-Ig 的性质。将C57BL6 J(H-2^b) 小鼠的脾细胞经尾静脉注射入亚致死剂量照射的BALB/c(H-2^d) 小鼠体内建立急性GVHD 模型,通过体内注射CD40-Ig 融合蛋白评价其对急性GVHD 小鼠的保护效果。结果: 按上述方法分别构建了哺乳动物表达载体pIG/40Ig 和p 3.1/40Ig。ELISA 和Western blot 确定在COS-7 和CHO 细胞中表达了CD40-Ig 融合蛋白。SDS-PAGE 结果显示该蛋白具有通过二硫键结合的二聚体结构并以同源二聚体的形式存在。纯化的CD40-Ig 可与CD40L 结合。体内应用CD40-Ig 融合蛋白治疗可延缓小鼠GVHD 病情发展并显著延长小鼠的平均存活时间。结论: CD40/CD40L 相互作用在GVHD 的病理过程中可能扮演了十分重要的角色, 提示人CD40-Ig 融合蛋白在临床预防和治疗GVHD方面的巨大应用潜力。

关键词: 生物医学工程学, CD40-Ig, 融合蛋白, 移植物抗宿主病

Abstract: AIM: To clone and express human CD40-Ig fusion protein, and further investigate its protective effects on graft-versus-host disease in a murine model. METHODS: Human CD40 gene extracellular region was cloned from Daudi cell line by RT-PCR and inserted into plasmid pIG1, which contains genomic human IgG1 Fc fragment.Then a transient vector containing CD40-Fc fusion gene was constructed and transfected into COS-7 cells.The secreted expression of CD40-Ig fusion protein was detected through indirect sandwich ELISA.In order to obtain plentiful CD40-Ig fusion protein, a constitutive vector was also generated by ligating the CD40-Fc fusion gene into pcDNA3.1, and hence transfecting it into CHO cells.Positive recombinant CHO cells, which secrete CD40-Ig fusion protein, were selected out and cultured on a large scale with serum-free medium, culture supernatant was harvested and purified by protein A affinity chromatography.SDS-PAGE, Western blot and ligand binding assay were used to identify the qualities of CD40-Ig.Murine acute graft-versus-host disease (GVHD) was induced by intravenous (iv) injection of C57BL/6J (H-2^b) spleen cells into sub-lethally irradiated BALB/c (H-2^d) mice. Protective effects against murine graft-versus-host disease by in vivo administration of CD40-Ig were evaluated. RESULTS: Mammalian expression vectors pIG/40-Ig and p3.1 40-Ig were constructed as described above.Chimeric proteins were expressed in COS-7 cell and CHO cell culture supernatant and confirmed by ELISA and Western blot.SDS-PAGE showed that fusion protein has a disulfide- bonded dimeric structure and existed as homodimer. Purified CD40-Ig could bind to CD40L expressed on Jurkat cell line.In vivo administration of CD40-Ig could prevent the development of GVHD and significantly prolongs the mean survival time of mice with GVHD. CONCLUSION: The CD40/CD40L interactions play a pivotal role in the pathogenesis of GVHD, suggesting clinical potential for CD40-Ig in the prevention and treatment of human GVHD.

Key words: biomedical engineering, CD40-Ig, fusion protein, graft-versus-host disease

中图分类号:

R318

刘荷中, 毛宁, 侯春梅, 李秀森, 沈倍奋, 唐佩弦. 阻断CD40/CD40L 相互作用延长移植物抗宿主病小鼠存活时间[J]. 中国临床药理学与治疗学, 2003, 8(1): 6-10.

LIU He-Zhong, MAO Ning, HOU Chun-Mei, LI Xiu-Sen, TANG Pei-Xian, SHEN Bei-Fen. Blockade of CD40/CD40L interactions prolongs the survival time of mice with graft-versus-host disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(1): 6-10.

参考文献

[1] James LM, Ferrari KR, Cooke LP, et al.The immunopathopjhsisology of acute graft-versus-host disease[J].Stem cells, 1996;14:473-89
[2] Yamada AA, Sayegh MH.The CD154-CD40 costimulatory pathway in transplantation[J].Transplantation, 2002;73(Suppl):S36-9
[3] Larsen CP, Pearson TC.The CD40 pathway in allograft rejection, acceptance, and tolerance [J].Curr Opin Immunol, 1997;9:641-7
[4] Banchereau J, Baznn F, Blanchard D, et al.The CD40 antigen and its ligand[J].Annu Rev Immunol, 1994;12:881-920
[5] Grewal IS, Flavell RA.A central role of CD40 ligand in the regulation of CD4 + T cell responses[J].Immunol Today, 1996;17:59-70
[6] Speiser DE, Bachmann MF, Shahinian A, et al.Acute graftversus- host disease without costimulation via CD28[J].Transplantation, 1997;63:1042-4
[7] Bergstrom DE, Grieco DA, Sonti MM, et al.The mouse Y chromosome:enrichment, sizing, and cloning by bivariate flow cytometry[J].Genomics, 1998;48:304-13
[8] Hill GR, Ferrara JLM.The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease:rationale for the use of cytokine shields in allogeneic bone marrow transplantation[J].Blood, 2000;95:2754-9
[9] Seung E, Iwakoshi N, Woda BA, et al.Allogeneic hematopoietic chimerism in mice treated with sublethal myeloabliation and anti-CD154 antibody:absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted.NOD/Lt mice [J].Blood, 2000;95:2175-82
[10] Blazar BR, Taylor PA, Noelle RJ, et al.CD4+ T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40: CD154) antibody lose their graft-versus-host disease lethality capacity but retain nomnal antigen response[J].J Clin Invest, 1998;102:473-82
[11] Durie FH, Aruffo A, Ledbetter J, et al.Antibody to the ligand of CD40L, gp39, blocks the occurrence of the acute and chronic forms of graft-versus-host disease[J].J Clin Invest, 1994; 94:1333-8
[12] Koenen HJPM, Joosten I.Blockade of CD86 and CD40 induces alloantigen-specific immunoregulatory T cells that remain anergic even after reversal of hyporesponsiveness[J].Blood, 2000; 95:3153-61
[13] Yuan X, Dong VM, Coito AJ, et al.A novel CD154 monoclonal antibody in acute and chronic rat vascularized cardiac allograft rejection[J].Transplantation, 2002;73:1736-42
[14] 衣京梅, 刘荷中, 唐锁勤, 等.小鼠移植物抗宿主病模型的建立及其初步应用[J].解放军医学杂志, 2002;27:494-6